James LeBar is Director at Zomedica Pharmaceuticals Corp. (ZOM). They have made 1 open-market trade across 1 company since 2018, most recently 2018-08-28.
CIK 0001721721
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ZOM | 20,000 | $2K |
Shares reported on the most recent Form 4, priced at the 2018-08-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZOM | SELL | 2018-08-28 | 2018-08-30 | $2.15 | $430K | +1.4% | -10.7% | -19.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.